1024. Evaluation of Management of Community Acquired Pneumonia Prior to Implementation of an Antimicrobial Stewardship Program Initiative: A Retrospective Assessment
Session: Poster Abstract Session: Antibiotic Stewardship: General Acute Care Implementation and Outcomes
Friday, October 28, 2016
Room: Poster Hall
  • Cap Poster App Upload.pdf (369.5 kB)
  • Background: Community acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality in the United States. Studies have shown that interventions such as shorter antibiotic therapy and early intravenous (IV) to oral conversion can be safely performed. We evaluated areas of improvement at our institutions that could help optimize patient management while reducing collateral damage associated with excessive antibiotic usage.

    Methods: In this retrospective analysis, all patients aged 18 years and older with a primary ICD-9 code for CAP admitted March 1st, 2014 to October 31st, 2014 were analyzed. The primary outcome was duration of antibiotic therapy for CAP (appropriate treatment duration defined as 5-7 days). Secondary objectives included duration of intravenous antibiotic therapy, duration of inpatient length of stay, and 30-day readmission rate related to CAP.

    Results: Of the 141 patients evaluated, 98 patients met inclusion criteria. The mean age was 63.8 (SD: 16.9 years). Chronic lung disease was present in 53(54%) of patients, while 17 (17.4%) required use of supplemental oxygen at home. The primary and secondary outcomes can be seen in Table 1.

    Table 1: Treatment duration and outcomes


    CAP (n=98)

    Duration of total antibiotics (SD), d

    10.1 (3.4)

    Duration of IV antibiotics (SD), d

    4.9 (3.3)

    Duration 0 - 1 days, n (%)

    0 (0.0)

    Duration 2 - 5 days, n (%)

    5 (5.1)

    Duration 6-7 days, n (%)

    21 (21.4)

    Duration 8-10, n (%)

    34 (34.7)

    Duration 11-14, n (%)

    25 (25.5)

    Duration > 14, n (%)

    13 (13.3)

    Inpatient length of stay (SD), d

    4.5 (3.1)

    Readmission within 30 days, n (%)

    14 (14.3)

    CAP related 30-day readmission, n (%)

    9 (9.2)

    Outcomes are presented as means; SD = Standard deviation

    Conclusion: We were surprised to identify the treatment duration in our cohort was ≤ 7 days in only 26% of patients, while 38% received >10 days of therapy. Our findings are concerning given the available data demonstrating that short-course therapy with 5 - 7 days is clinically as effective as long-course therapy and associated with fewer adverse events. The management of CAP represents a significant opportunity for antimicrobial stewardship intervention.

    Thomas Walsh, MD, PhD (hon), FIDSA, FAAM1,2, Briana Disilvio, MD1,2, Daniel Speredelozzi, MD1,2, Crystal Hammer, MD1,2, Kurt Hu, MD1,2, Rasha Abdulmassih, MD1,2, Jina Makadia, MD1,2, Rikinder Sandhu, MD2,3, Mouhib Naddour, MD1,2, Swati Vishwanathan, MD1,2, Noreen Chan-Tompkins, PharmD, BCPS-AQ ID1, Tamara Trienski, PharmD1, Matthew Moffa, DO1,2 and Derek Bremmer, PharmD2, (1)Allegheny General Hospital, Pittsburgh, PA, (2)Western Pennsylvania Hospital, Pittsburgh, PA, (3)Division of Infectious Diseases, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA


    T. Walsh, None

    B. Disilvio, None

    D. Speredelozzi, None

    C. Hammer, None

    K. Hu, None

    R. Abdulmassih, None

    J. Makadia, None

    R. Sandhu, None

    M. Naddour, None

    S. Vishwanathan, None

    N. Chan-Tompkins, None

    T. Trienski, None

    M. Moffa, None

    D. Bremmer, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.